Literature DB >> 14578863

PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.

Hiroyuki Okamoto1, Kohichiroh Yasui, Chen Zhao, Shigeki Arii, Johji Inazawa.   

Abstract

We investigated 39 primary hepatocellular carcinomas (HCCs) for aberrations in DNA copy number, using comparative genomic hybridization (CGH). Gain of DNA at 8q was common in these tumors; high-level gains, indicative of gene amplification, occurred most frequently at 8q23-q24. Gains of 8q correlated with large (>5 cm) tumor size. To identify targets of the amplification events involving 8q, we determined expression levels of 14 candidate genes within that region in a total of 41 HCCs by means of real-time quantitative reverse-transcription polymerase chain reactions (RT-PCR). Significant correlation was found between elevated levels of expression and increases in copy number for PTK2 (located at 8q24.3) and EIF3S3 (at 8q23.3), but for none of the other candidates, which included MYC (8q24.1). Southern blot analyses confirmed that PTK2 and EIF3S3 were amplified, respectively, in 5 (19%) and 7 (26%) of the 27 tumors examined in accordance with expression patterns, an indication that expression of PTK2 and EIF3S3 was probably up-regulated by the amplification mechanism. When we analyzed potential relationships between elevated expression of PTK2 and EIF3S3 and clinicopathologic parameters, high expression of the 2 transcripts was significantly associated with large (>5 cm) tumor size and with hepatitis B virus (HBV) infection. In conclusion, PTK2 and EIF3S3, which, respectively, encode focal adhesion kinase and the p40 subunit of the eukaryotic initiation factor 3, were probable targets within the amplification at 8q23-q24 and may be involved in progression of HCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578863     DOI: 10.1053/jhep.2003.50457

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a.

Authors:  Hima Anbunathan; Ruth Verstraten; Arun D Singh; J William Harbour; Anne M Bowcock
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells.

Authors:  Pavel Klener; Maud Szynal; Yvette Cleuter; Makram Merimi; Hugues Duvillier; Françoise Lallemand; Claude Bagnis; Philip Griebel; Christos Sotiriou; Arsène Burny; Philippe Martiat; Anne Van den Broeke
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

5.  An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3.

Authors:  Lili Zhang; Zeljka Smit-McBride; Xiaoyu Pan; Jeanette Rheinhardt; John W B Hershey
Journal:  J Biol Chem       Date:  2008-06-10       Impact factor: 5.157

6.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Authors:  Richard Marcotte; Kevin R Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L Y Koh; Dewald van Dyk; Bodhana Fedyshyn; Marianna Luhova; Glauber C Brito; Franco J Vizeacoumar; Frederick S Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L Wrana; Robert Rottapel; Benjamin G Neel; Jason Moffat
Journal:  Cancer Discov       Date:  2011-12-29       Impact factor: 39.397

7.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

8.  A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.

Authors:  Kun Zhao; Yu Zhao; Jia-Yi Zhu; Hui Dong; Wen-Ming Cong; Yi Yu; Hui Wang; Zhong-Zheng Zhu; Qing Xu
Journal:  Curr Med Sci       Date:  2018-08-20

9.  CD1d gene is a target for a novel amplicon at 1q22-23.1 in human hepatocellular carcinoma.

Authors:  Shi-Guang Zhang; Wen-Qin Song; Ying-Tang Gao; Bin Yang; Zhi Du
Journal:  Mol Biol Rep       Date:  2010-01       Impact factor: 2.316

10.  MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.

Authors:  Federico Cappuzzo; Marileila Varella-Garcia; Elisa Rossi; Sujatha Gajapathy; Marialuisa Valente; Harry Drabkin; Robert Gemmill
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.